Author of

• 31272

  +

  P1.11 - Screening and Early Detection (ID 177)

  • Event: WCLC 2019
  • Type: Poster Viewing in the Exhibit Hall
  • Track: Screening and Early Detection
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/08/2019, 09:45 - 18:00, Exhibit Hall

  • 31320

    +

    P1.11-38 - Frequency and Prognostic Impact of Concomitant Mutations in KRAS and TP53 or STK11 in Brazilian Lung Adenocarcinoma Patients (ID 2576)

    09:45 - 18:00  |  Author(s): Juliano Prudencio Chinoca
    • Abstract

    Background
    

    Previous studies reported that co-occurring genomic alterations in KRAS and STK11/LKB1 or TP53 tumor suppressor genes define subgroups of KRAS-mutant lung adenocarcinomas (LADC) with distinct biology, therapeutic vulnerabilities, and immune profiles. The impact of concomitant STK11, TP53 and KRAS mutations in Brazilian lung cancer patients remains poorly explored.

    Aims: In our preliminary study, we investigated the frequency of STK11 and TP53 in KRAS mutant or wild-type LADC. STK11 and TP53 mutational status was correlated with clinico-pathological characteristics and overall survival (OS).

    Method
    

    This is a retrospective analysis which included 27 consecutive LADC patients treated with platinum-based chemotherapy and/or immunotherapy. Mutational status analysis was performed using the Illumina TruSight Tumor 26™ panel based on multiplex-PCR. This customized multiple genes panel covers 26 critical oncogenes or tumor supressor genes including: exons 2–4 of KRAS, exons 1–9 of STK11 and 1–11 of TP53, specifically considered in the current study. Kaplan-Meier method was used to calculate overall survival and the univariate Cox model was used to compare survival.

    Result
    

    Among the 27 patients included, 23 (85%) were KRAS mutant (KRASmut), 15 (55.6%) were TP53 mutant (TP53mut) and 5 (18%) harbored a STK11 mutation (STK11mut). From all mutant cases, 10 (37%) were KRASmut only; 4 (14.8%) TP53mut only; 2 (7.4%) KRAS+STK11; 8 (29.6%) KRAS+TP53; 3 (11%) KRAS+TP53+STK11. No associations were observed between KRAS, TP53 and STK11 status and clinico-pathological variables. OS was shorter for TP53mut compared with wild-type patients in Cox univariate analysis (p=0.006). KRAS and STK11 status did not impact OS and progression-free survival. The co-occurrence of KRAS and TP53 mutations appears to have a detrimental effect in OS (p=0.064).

    Conclusion
    

    In this cohort, KRAS, TP53, and STK11 mutations were not associated with clinico-pathological features. TP53 mutations may identify a more aggressive molecular subtype of LADC.

• 31322

  +

  P2.11 - Screening and Early Detection (ID 178)

  • Event: WCLC 2019
  • Type: Poster Viewing in the Exhibit Hall
  • Track: Screening and Early Detection
  • Presentations: 1
  • Now Available
  • Moderators:
  • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall

  • 32090

    +

    P2.11-28 - Late-Breaking Abstract - Clinical Potential of Sputum Hyaluronan Measurement in the Diagnosis and Prognosis of Patients with NSCLC (Now Available) (ID 2622)

    10:15 - 18:15  |  Author(s): Juliano Prudencio Chinoca
    • Abstract
    • Slides

    Background
    

    Lung cancer is the most frequently diagnosed and also the most lethal due to late diagnosis. Many efforts are being made to mitigate this problem. In this scenario, sputum is a potentially attractive source of biomarkers present in the extracellular matrix such as hyaluronan (HA). The aim of this study is to validate HA levels in sputum’s patients with non-small cell lung cancer (NSCLC) at the time of diagnosis and after first-line treatment evaluation response and correlate the values response rate in patients submitted to definitive treatment with chemotherapy and/or radiotherapy, progression and recurrence. We also evaluated the HA concentrations in chronic obstructive pulmonary Disease (COPD) and healthy volunteers and its impact on the screening and diagnosis of lung cancer patients.

    Method
    

    HA was examined in sputum samples of 64 NSCLC, 14 COPD patients and 15 healthy controls. All the patients and healthy controls selected underwent a sputum induction.The levels of HA were measured in ng/ug of protein by a noncompetitive ELISA-like fluorometric assay.

    Result
    

    A significant different concentration pattern of HA in the sputum was found among NSCLC (median: 33.25 ng/mg), COPD (median:16.6ng/ug) and healthy individuals (median: 12.2 ng/ug), (p<0.001, Fig. 1A), as well as NSCLC before first-line treatment (median:33.25ng/mg) and after 6 months treatment regimens with good response (median:6.2ng/ug), (p<0.001, Fig 2).

    Conclusion
    

    Based on the results obtained so far, we rely on the clinical potential of sputum as a screening tool in the early detection of lung cancer.
    
    Fig. 1A
    
    
    Fig. 2
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.